Contact

Press release from PAXMAN AB’s 2021 Annual General Meeting

PAXMAN´s AGM was held today, 26 May 2021, at NetPort in Karlshamn. Almost 53 % of all issued shares were represented at the meeting. After the formal AGM, CEO Richard Paxman gave a company presentation and responded to questions from the attending shareholders.

In accordance with the proposal submitted by the Nomination Committee, the AGM resolved that the Board of Directors shall consist of six Board Members without deputy members. The Board was re-elected in its entirety, and will thus consist of the following members up to the AGM 2022: Per-Anders Johansson (Chairman of the Board), Robert Kelly, Björn Littorin, Glenn Paxman, Richard Paxman and Maria Bech.
Also in accordance with the Nomination Committee’s proposal, the registered accountancy firm BDO Mälardalen AB was re-elected. BDO has notified that Niclas Nordström will remain chief auditor.
The Meeting further resolved that the total fees payable to the Board, excluding travel expenses, will be 350,000 SEK per annum, of which 125,000 SEK payable to the Chairman of the Board and 75,000 SEK to each of the Board Members elected by the AGM who are not employed by the company.
The Meeting finally resolved to approve the boards proposal to authorize the board to decide on a directed share issue involving an increase of the share capital by a maximum of SEK 1,761,250 through the issuance of a maximum of 1,761,250 new shares. The authorization entails a maximum total increase of the total number of shares in the Company by 10.0 % (9.1 % after the exercise of the authorization). The issue should be possible with deviation from the shareholders’ preferential rights. The authorization must be exercisable on one or more occasions at the latest until the next AGM, and the basis for the issue price for the exercise of the authorization shall be the market value of the share with or without consideration of market discount.
All resolutions made by the AGM were unanimous.

Press release from PAXMAN AB’s 2021 Annual General Meeting Press release from PAXMAN AB’s 2021 Annual General Meeting
What we do
Paxman are world leaders in chemotherapy side effect management on an ambitious journey to change the face of cancer through cryotherapy-based treatments. The Paxman mission is to democratise access to scalp cooling globally.
Learn more →
Financial Information
Read the latest Paxman financial reports. In these comprehensive documents, you will find a detailed overview of our financial performance, key milestones, and a strategic outlook for the future. Reports are published quarterly and annually.
Read reports  →
Investing in Paxman
Paxman has treated 100,000+ patients and installed 5,000+ systems in more than 65 countries worldwide. We are helping to manage the trauma of chemotherapy hair loss. By investing in Paxman, you're not just supporting a company; you're joining us in changing the face of cancer.
Visit the Investor Centre →
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram